Status:

COMPLETED

Premature Coronary Artery Disease (CAD) in Severe Psoriasis

Lead Sponsor:

University of Michigan

Conditions:

Psoriasis

Coronary Artery Disease

Eligibility:

All Genders

18-55 years

Brief Summary

The purpose of this study is to compare the prevalence and severity of CAD (coronary artery disease) in patients with and without severe psoriasis, otherwise matched for cardiovascular risk factors.

Detailed Description

To establish the relationship between psoriasis and coronary disease by comparing the prevalence and severity of CAD (coronary artery disease) in patients with and without severe psoriasis, otherwise ...

Eligibility Criteria

Inclusion

  • Patients with severe psoriasis as determined by more than two episodes of systemic or inpatient treatment and 10% or more body surface area involvement.
  • Male or female ages 18 to 55 (because CAD risk has been shown to be greatest in younger psoriasis patients in earlier studies, this pilot study will focus on young individuals).
  • Able to give informed consent

Exclusion

  • Prior diagnosis of CAD (coronary artery disease) or heart disease based upon one or more of the following:
  • coronary arteriography
  • percutaneous coronary intervention
  • cardiac surgery including bypass graft surgery
  • valve surgery
  • congenital heart disease repair
  • stress ECG or imaging
  • myocardial infarction
  • angina or unstable angina
  • congestive heart failure
  • cardiomyopathy
  • History of anti-oxidants such as fish oil or biologic therapy Tumor Necrosis Factor alpha inhibitors (such as etanercept, adalimumab, or infliximab). A recent review by Sattar et al \[22\] has shown preliminary evidence that TNF (tumor necrosis factor) blockade can modulate nontraditional cardiovascular risk factors such as C-reactive protein(CRP), Interleukin-6(IL-6), Apolipoprotein AI(ApoAI), Lipoprotein(a)(Lp\[a\]), Sex Hormone Binding Globulin (SHBG), and homocysteine to exert a possible vascular and metabolic protective effect.
  • Pustular and erythrogenic psoriasis
  • Unable to give informed consent
  • Contraindications to coronary CT, including:
  • Irregular heart rate, such as multiple PVCs (premature ventricular contractions), atrial fibrillation
  • Active heart failure
  • Serum creatinine \> 1.5mg/dl
  • Weight \> 320 lbs (due to degradation in CT (computerized tomography)image quality by image noise)
  • History of severe allergy to intravenous contrast media
  • High irregular heart rate with contraindications to beta-blockers
  • Pregnant

Key Trial Info

Start Date :

November 1 2009

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

August 1 2016

Estimated Enrollment :

46 Patients enrolled

Trial Details

Trial ID

NCT00893126

Start Date

November 1 2009

End Date

August 1 2016

Last Update

October 19 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Michigan Hospital

Ann Arbor, Michigan, United States, 48109